Post by icemandios on Mar 10, 2022 17:44:36 GMT
ViewRay to Host a Virtual Clinical Data Event for Investors and Analysts on March 16, 2022
PR Newswire
CLEVELAND , March 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Wednesday, March 16, 2022 . The event will begin at 4:00 pm ET .
The Virtual Clinical Data Event will be hosted by the ViewRay leadership team and will feature the clinical work of Amar Kishan , M.D., Associate Professor and Chief of the Genitourinary Oncology Service at UCLA . The event will feature a fireside chat between Dr. Kishan and Dr. Himanshu Nagar , M.D., radiation oncologist and Assistant Professor, Weill Cornell Medicine, New York-Presbyterian, regarding the MIRAGE and SCIMITAR clinical trials and the future of prostate cancer radiation therapy.
To participate in the event, guests must register either on the company's website or at viewray.zoom.us/webinar/register/WN_oqm7dpQNTYm8tduBCKwqKw . A replay of the event will be available on the company's website following the event.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
PR Newswire
CLEVELAND , March 10, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the company will host a Virtual Clinical Data Event for Investors and Analysts on Wednesday, March 16, 2022 . The event will begin at 4:00 pm ET .
The Virtual Clinical Data Event will be hosted by the ViewRay leadership team and will feature the clinical work of Amar Kishan , M.D., Associate Professor and Chief of the Genitourinary Oncology Service at UCLA . The event will feature a fireside chat between Dr. Kishan and Dr. Himanshu Nagar , M.D., radiation oncologist and Assistant Professor, Weill Cornell Medicine, New York-Presbyterian, regarding the MIRAGE and SCIMITAR clinical trials and the future of prostate cancer radiation therapy.
To participate in the event, guests must register either on the company's website or at viewray.zoom.us/webinar/register/WN_oqm7dpQNTYm8tduBCKwqKw . A replay of the event will be available on the company's website following the event.
About ViewRay®
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.